Regeneron Pharmaceuticals, Inc. (0R2M.L)
USD 607.93
(4.12%)
USD 607.93
(4.12%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 11.3 Billion USD | 6.49% |
| 2022 | 10.61 Billion USD | -22.16% |
| 2021 | 13.63 Billion USD | 84.82% |
| 2020 | 7.37 Billion USD | 4.18% |
| 2019 | 7.08 Billion USD | 12.82% |
| 2018 | 6.27 Billion USD | 14.64% |
| 2017 | 5.47 Billion USD | 20.05% |
| 2016 | 4.56 Billion USD | 22.9% |
| 2015 | 3.71 Billion USD | 41.94% |
| 2014 | 2.61 Billion USD | 34.12% |
| 2013 | 1.94 Billion USD | 50.65% |
| 2012 | 1.29 Billion USD | 193.03% |
| 2011 | 441.6 Million USD | -3.36% |
| 2010 | 456.98 Million USD | 21.03% |
| 2009 | 377.58 Million USD | 58.96% |
| 2008 | 237.53 Million USD | 89.99% |
| 2007 | 125.02 Million USD | 126.08% |
| 2006 | 55.3 Million USD | -2.36% |
| 2005 | 56.63 Million USD | -64.34% |
| 2004 | 158.8 Million USD | 212.48% |
| 2003 | 50.82 Million USD | 227.77% |
| 2002 | 15.5 Million USD | 0.27% |
| 2001 | 15.46 Million USD | -64.62% |
| 2000 | 43.71 Million USD | 41.46% |
| 1999 | 30.9 Million USD | -6.93% |
| 1998 | 33.2 Million USD | 8.85% |
| 1997 | 30.5 Million USD | 32.61% |
| 1996 | 23 Million USD | -16.06% |
| 1995 | 27.4 Million USD | 18.1% |
| 1994 | 23.2 Million USD | 118.87% |
| 1993 | 10.6 Million USD | -7.83% |
| 1992 | 11.5 Million USD | 309.09% |
| 1991 | -5.5 Million USD | -323.08% |
| 1990 | -1.3 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 2.94 Billion USD | 13.44% |
| 2024 Q1 | 2.59 Billion USD | -10.98% |
| 2024 Q3 | 3.49 Billion USD | 9.62% |
| 2023 Q3 | 3.15 Billion USD | 14.44% |
| 2023 FY | 11.3 Billion USD | 6.49% |
| 2023 Q2 | 2.75 Billion USD | 1.8% |
| 2023 Q1 | 2.7 Billion USD | -5.89% |
| 2023 Q4 | 2.91 Billion USD | -7.41% |
| 2022 Q4 | 2.87 Billion USD | 9.75% |
| 2022 Q2 | 2.56 Billion USD | -0.0% |
| 2022 Q1 | 2.56 Billion USD | -35.5% |
| 2022 Q3 | 2.61 Billion USD | 2.28% |
| 2022 FY | 10.61 Billion USD | -22.16% |
| 2021 Q1 | 2.22 Billion USD | 7.29% |
| 2021 Q3 | 2.99 Billion USD | -32.51% |
| 2021 Q4 | 3.96 Billion USD | 32.32% |
| 2021 FY | 13.63 Billion USD | 84.82% |
| 2021 Q2 | 4.44 Billion USD | 100.15% |
| 2020 Q3 | 2.02 Billion USD | 20.49% |
| 2020 FY | 7.37 Billion USD | 4.18% |
| 2020 Q2 | 1.67 Billion USD | 4.07% |
| 2020 Q1 | 1.61 Billion USD | -17.2% |
| 2020 Q4 | 2.06 Billion USD | 2.47% |
| 2019 FY | 7.08 Billion USD | 12.82% |
| 2019 Q4 | 1.94 Billion USD | 6.8% |
| 2019 Q3 | 1.82 Billion USD | 2.28% |
| 2019 Q2 | 1.78 Billion USD | 16.22% |
| 2019 Q1 | 1.53 Billion USD | -15.35% |
| 2018 Q4 | 1.81 Billion USD | 16.58% |
| 2018 FY | 6.27 Billion USD | 14.64% |
| 2018 Q3 | 1.55 Billion USD | 2.42% |
| 2018 Q2 | 1.51 Billion USD | 8.58% |
| 2018 Q1 | 1.39 Billion USD | -5.43% |
| 2017 Q1 | 1.23 Billion USD | 7.18% |
| 2017 FY | 5.47 Billion USD | 20.05% |
| 2017 Q3 | 1.39 Billion USD | 2.14% |
| 2017 Q4 | 1.47 Billion USD | 5.75% |
| 2017 Q2 | 1.36 Billion USD | 10.72% |
| 2016 Q4 | 1.15 Billion USD | -2.02% |
| 2016 Q1 | 1.08 Billion USD | 10.32% |
| 2016 Q2 | 1.14 Billion USD | 5.0% |
| 2016 FY | 4.56 Billion USD | 22.9% |
| 2016 Q3 | 1.17 Billion USD | 2.82% |
| 2015 Q3 | 1.02 Billion USD | 13.03% |
| 2015 FY | 3.71 Billion USD | 41.94% |
| 2015 Q1 | 785.65 Million USD | 5.76% |
| 2015 Q2 | 909.77 Million USD | 15.8% |
| 2015 Q4 | 987.24 Million USD | -4.0% |
| 2014 Q4 | 742.85 Million USD | 10.84% |
| 2014 FY | 2.61 Billion USD | 34.12% |
| 2014 Q1 | 582.16 Million USD | 3.53% |
| 2014 Q2 | 619.32 Million USD | 6.38% |
| 2014 Q3 | 670.19 Million USD | 8.21% |
| 2013 Q4 | 562.29 Million USD | 0.69% |
| 2013 FY | 1.94 Billion USD | 50.65% |
| 2013 Q3 | 558.45 Million USD | 33.59% |
| 2013 Q2 | 418.02 Million USD | 1.81% |
| 2013 Q1 | 410.6 Million USD | 6.81% |
| 2012 FY | 1.29 Billion USD | 193.03% |
| 2012 Q4 | 384.43 Million USD | -5.67% |
| 2012 Q1 | 219.49 Million USD | 82.93% |
| 2012 Q2 | 282.55 Million USD | 28.73% |
| 2012 Q3 | 407.54 Million USD | 44.23% |
| 2011 Q1 | 111.82 Million USD | -15.97% |
| 2011 Q4 | 119.98 Million USD | 17.2% |
| 2011 Q2 | 107.41 Million USD | -3.94% |
| 2011 FY | 441.6 Million USD | -3.36% |
| 2011 Q3 | 102.38 Million USD | -4.68% |
| 2010 Q2 | 115.48 Million USD | 12.32% |
| 2010 FY | 456.98 Million USD | 21.03% |
| 2010 Q3 | 105.6 Million USD | -8.55% |
| 2010 Q4 | 133.07 Million USD | 26.01% |
| 2010 Q1 | 102.81 Million USD | 6.64% |
| 2009 Q1 | 74.58 Million USD | 35.11% |
| 2009 Q2 | 89.59 Million USD | 20.12% |
| 2009 Q3 | 116.98 Million USD | 30.57% |
| 2009 Q4 | 96.41 Million USD | -17.58% |
| 2009 FY | 377.58 Million USD | 58.96% |
| 2008 FY | 237.53 Million USD | 89.99% |
| 2008 Q4 | 55.2 Million USD | -15.45% |
| 2008 Q3 | 65.29 Million USD | 7.66% |
| 2008 Q2 | 60.64 Million USD | 7.56% |
| 2008 Q1 | 56.38 Million USD | -12.9% |
| 2007 Q3 | 22.31 Million USD | 0.52% |
| 2007 Q4 | 64.73 Million USD | 190.13% |
| 2007 FY | 125.02 Million USD | 126.08% |
| 2007 Q2 | 22.19 Million USD | 40.58% |
| 2007 Q1 | 15.78 Million USD | 59.22% |
| 2006 Q4 | 9.91 Million USD | -21.11% |
| 2006 FY | 55.3 Million USD | -2.36% |
| 2006 Q3 | 12.57 Million USD | -23.58% |
| 2006 Q2 | 16.44 Million USD | 0.49% |
| 2006 Q1 | 16.36 Million USD | 7.12% |
| 2005 Q3 | 12.94 Million USD | -11.86% |
| 2005 FY | 56.63 Million USD | -64.34% |
| 2005 Q2 | 14.69 Million USD | 7.09% |
| 2005 Q1 | 13.71 Million USD | -68.55% |
| 2005 Q4 | 15.27 Million USD | 18.0% |
| 2004 Q1 | 59.76 Million USD | 193.47% |
| 2004 FY | 158.8 Million USD | 212.48% |
| 2004 Q4 | 43.61 Million USD | 58.41% |
| 2004 Q3 | 27.53 Million USD | -1.28% |
| 2004 Q2 | 27.88 Million USD | -53.34% |
| 2003 Q2 | 10.27 Million USD | 8.48% |
| 2003 Q4 | 20.36 Million USD | 62.3% |
| 2003 FY | 50.82 Million USD | 227.77% |
| 2003 Q3 | 12.54 Million USD | 22.15% |
| 2003 Q1 | 9.47 Million USD | 197.24% |
| 2002 Q2 | 3.7 Million USD | 0.71% |
| 2002 Q1 | 3.68 Million USD | 13.68% |
| 2002 Q3 | 4.92 Million USD | 32.93% |
| 2002 Q4 | 3.18 Million USD | -35.36% |
| 2002 FY | 15.5 Million USD | 0.27% |
| 2001 Q3 | 4.2 Million USD | 8.01% |
| 2001 FY | 15.46 Million USD | -64.62% |
| 2001 Q1 | 6.89 Million USD | -35.41% |
| 2001 Q2 | 3.89 Million USD | -43.54% |
| 2001 Q4 | 3.23 Million USD | -22.99% |
| 2000 Q3 | 12.39 Million USD | -6.04% |
| 2000 Q2 | 13.19 Million USD | 77.13% |
| 2000 FY | 43.71 Million USD | 41.46% |
| 2000 Q1 | 7.44 Million USD | -36.89% |
| 2000 Q4 | 10.67 Million USD | -13.85% |
| 1999 Q1 | 4.2 Million USD | -27.59% |
| 1999 FY | 30.9 Million USD | -6.93% |
| 1999 Q4 | 11.8 Million USD | 14.56% |
| 1999 Q3 | 10.3 Million USD | 119.15% |
| 1999 Q2 | 4.7 Million USD | 11.9% |
| 1998 FY | 33.2 Million USD | 8.85% |
| 1998 Q3 | 9.5 Million USD | -22.76% |
| 1998 Q4 | 5.8 Million USD | -38.95% |
| 1998 Q1 | 5.6 Million USD | -46.67% |
| 1998 Q2 | 12.3 Million USD | 119.64% |
| 1997 Q3 | 8.1 Million USD | 32.79% |
| 1997 Q1 | 5.7 Million USD | -12.31% |
| 1997 FY | 30.5 Million USD | 32.61% |
| 1997 Q4 | 10.5 Million USD | 29.63% |
| 1997 Q2 | 6.1 Million USD | 7.02% |
| 1996 Q2 | 6.2 Million USD | 19.23% |
| 1996 Q4 | 6.5 Million USD | 4.84% |
| 1996 Q1 | 5.2 Million USD | -10.34% |
| 1996 FY | 23 Million USD | -16.06% |
| 1996 Q3 | 6.2 Million USD | 0.0% |
| 1995 FY | 27.4 Million USD | 18.1% |
| 1995 Q4 | 5.8 Million USD | -6.45% |
| 1995 Q3 | 6.2 Million USD | -18.42% |
| 1995 Q2 | 7.6 Million USD | 10.14% |
| 1995 Q1 | 6.9 Million USD | -10.39% |
| 1994 Q2 | 3.6 Million USD | 20.0% |
| 1994 Q4 | 7.7 Million USD | -13.48% |
| 1994 FY | 23.2 Million USD | 118.87% |
| 1994 Q3 | 8.9 Million USD | 147.22% |
| 1994 Q1 | 3 Million USD | 3.45% |
| 1993 Q2 | 1.3 Million USD | -38.1% |
| 1993 Q4 | 2.9 Million USD | 141.43% |
| 1993 Q3 | -7 Million USD | -638.46% |
| 1993 FY | 10.6 Million USD | -7.83% |
| 1993 Q1 | 2.1 Million USD | -8.7% |
| 1992 Q3 | 2.4 Million USD | -25.0% |
| 1992 Q1 | 3.5 Million USD | 216.67% |
| 1992 FY | 11.5 Million USD | 309.09% |
| 1992 Q4 | 2.3 Million USD | -4.17% |
| 1992 Q2 | 3.2 Million USD | -8.57% |
| 1991 Q1 | 2 Million USD | 53.85% |
| 1991 Q3 | -500 Thousand USD | 58.33% |
| 1991 Q4 | -3 Million USD | -500.0% |
| 1991 FY | -5.5 Million USD | -323.08% |
| 1991 Q2 | -1.2 Million USD | -160.0% |
| 1990 Q1 | 1.2 Million USD | 0.0% |
| 1990 FY | -1.3 Million USD | 0.0% |
| 1990 Q4 | 1.3 Million USD | 0.0% |
| 1990 Q3 | 1.3 Million USD | 8.33% |
| 1990 Q2 | 1.2 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| uniQure N.V. | 2.21 Million USD | -510121.219% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -3742085.43% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 13362.063% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -65154.345% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 3610770.927% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -76291.78% |
| Imunon, Inc. | -720 Thousand USD | 1569727.989% |
| Dynavax Technologies Corporation | 182.11 Million USD | -6105.571% |
| Editas Medicine, Inc. | -99.52 Million USD | 11454.996% |
| FibroGen, Inc. | 128.9 Million USD | -8667.3% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 118241.334% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 3729934.983% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | -511.746% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | -933.986% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | -2057.818% |
| Verastem, Inc. | -62 Thousand USD | 18228164.516% |
| Zoetis Inc. | 5.83 Billion USD | -93.716% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | -31.305% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 25034.142% |
| Homology Medicines, Inc. | -7.22 Million USD | 156434.209% |
| Nektar Therapeutics | 53.47 Million USD | -21032.802% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 3870442.466% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 57470.425% |
| Perrigo Company plc | 1.68 Billion USD | -572.542% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -15367.174% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 57.392% |
| Illumina, Inc. | 2.74 Billion USD | -311.859% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 25.766% |
| IQVIA Holdings Inc. | 5.23 Billion USD | -115.717% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -112441.326% |
| Waters Corporation | 1.76 Billion USD | -541.69% |
| Biogen Inc. | 7.3 Billion USD | -54.767% |
| Evolus, Inc. | 140.52 Million USD | -7942.213% |
| Adicet Bio, Inc. | -6.09 Million USD | 185429.616% |
| bluebird bio, Inc. | -4.03 Million USD | 280531.762% |
| Geron Corporation | -123.5 Million USD | 9250.709% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | -644.549% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | -3021.675% |
| Myriad Genetics, Inc. | 476.4 Million USD | -2272.25% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 2933.894% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | -421.024% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 36360.021% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | -493.445% |
| Agilent Technologies, Inc. | 3.46 Billion USD | -226.159% |
| OPKO Health, Inc. | 318.12 Million USD | -3452.481% |
| Exelixis, Inc. | 1.75 Billion USD | -542.98% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | -2274.773% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | -4521.588% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | -1351.663% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | -1674.461% |
| Blueprint Medicines Corporation | 236.58 Million USD | -4676.908% |
| Insmed Incorporated | 239.63 Million USD | -4616.089% |
| TG Therapeutics, Inc. | 219.1 Million USD | -5057.913% |
| Incyte Corporation | 3.44 Billion USD | -228.467% |
| Emergent BioSolutions Inc. | 343.9 Million USD | -3186.246% |